Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 11;20(1):404.
doi: 10.1186/s12885-020-06892-4.

Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases

Goda G Kalinauskaite  1   2 , Ingeborg I Tinhofer  3   4 , Markus M Kufeld  5 , Anne A Kluge  3   5 , Arne A Grün  3   5 , Volker V Budach  3   5 , Carolin C Senger  3   5 , Carmen C Stromberger  3   5
Affiliations

Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases

Goda G Kalinauskaite et al. BMC Cancer. .

Abstract

Background: Patients with oligometastatic disease can potentially be cured by using an ablative therapy for all active lesions. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment option that lately proved to be as effective and safe as surgery in treating lung metastases (LM). However, it is not clear which patients benefit most and what are the most suitable fractionation regimens. The aim of this study was to analyze treatment outcomes after single fraction radiosurgery (SFRS) and fractionated SBRT (fSBRT) in patients with lung oligometastases and identify prognostic clinical features for better survival outcomes.

Methods: Fifty-two patients with 94 LM treated with SFRS or fSBRT between 2010 and 2016 were analyzed. The characteristics of primary tumor, LM, treatment, toxicity profiles and outcomes were assessed. Kaplan-Meier and Cox regression analyses were used for estimation of local control (LC), overall survival (OS) and progression-free survival.

Results: Ninety-four LM in 52 patients were treated using SFRS/fSBRT with a median of 2 lesions per patient (range: 1-5). The median planning target volume (PTV)-encompassing dose for SFRS was 24 Gy (range: 17-26) compared to 45 Gy (range: 20-60) in 2-12 fractions with fSBRT. The median follow-up time was 21 months (range: 3-68). LC rates at 1 and 2 years for SFSR vs. fSBRT were 89 and 83% vs. 75 and 59%, respectively (p = 0.026). LM treated with SFSR were significantly smaller (p = 0.001). The 1 and 2-year OS rates for all patients were 84 and 71%, respectively. In univariate analysis treatment with SFRS, an interval of ≥12 months between diagnosis of LM and treatment, non-colorectal cancer histology and BED < 100 Gy were significantly associated with better LC. However, none of these parameters remained significant in the multivariate Cox regression model. OS was significantly better in patients with negative lymph nodes (N0), Karnofsky performance status (KPS) > 70% and time to first metastasis ≥12 months. There was no grade 3 acute or late toxicity.

Conclusions: Longer time to first metastasis, good KPS and N0 predicted better OS. Good LC and low toxicity rates were achieved after short SBRT schedules.

Keywords: CyberKnife; Lung metastases; Oligometastases; Radiosurgery; SBRT.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Treatment plan and dose distribution for (a) CyberKnife, (b) Novalis treatment system
Fig. 2
Fig. 2
Kaplan-Meier curves of (a) local control SFRS vs. fSBRT, (b) overall survival, (c) progression-free survival
See this image and copyright information in PMC

References

    1. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi: 10.1126/science.1203543. - DOI - PubMed
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed
    1. Lindsay DP, Caster JM, Wang K, Myung JH, Chen RC, Chera B, et al. Nanotechnology-based quantification of circulating tumor cells in oligometastatic patients undergoing definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(2):S51.
    1. Herold CJ, Bankier AA, Fleischmann D. Lung metastases. Eur Radiol. 1996;6(5):596–606. doi: 10.1007/BF00187656. - DOI - PubMed
    1. Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6(1):570–583. doi: 10.18632/oncotarget.2677. - DOI - PMC - PubMed